Technical Analysis for UTHR - United Therapeutics Corporation

Grade Last Price % Change Price Change
C 364.33 1.00% 3.62
UTHR closed up 1.0 percent on Wednesday, November 20, 2024, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
7 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Down

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness 1.00%
Outside Day Range Expansion 1.00%
Gapped Down Weakness 1.00%
Oversold Stochastic Weakness 1.00%
Fell Below 50 DMA Bearish 1.43%
Down 3 Days in a Row Weakness 1.43%
Down 4 Days in a Row Weakness 1.43%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 18 hours ago
60 Minute Opening Range Breakout about 21 hours ago
Up 1% about 21 hours ago
50 DMA Resistance about 21 hours ago
Rose Above Previous Day's High about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

United Therapeutics Corporation Description

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Alcohol Infectious Diseases Organic Compounds Chemical Compounds Hypertension Blastoma Hepatitis C Pulmonary Arterial Hypertension Brain Cancer Pulmonary Hypertension Lung Diseases Neuroblastoma Treprostinil Chronic And Life Threatening Conditions Oral Therapy Treatment Of Infectious Diseases

Is UTHR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 417.815
52 Week Low 208.6249
Average Volume 358,542
200-Day Moving Average 300.93
50-Day Moving Average 363.86
20-Day Moving Average 375.80
10-Day Moving Average 384.81
Average True Range 11.05
RSI (14) 44.44
ADX 24.9
+DI 23.43
-DI 32.43
Chandelier Exit (Long, 3 ATRs) 384.67
Chandelier Exit (Short, 3 ATRs) 375.17
Upper Bollinger Bands 415.71
Lower Bollinger Band 335.88
Percent B (%b) 0.36
BandWidth 21.25
MACD Line 2.35
MACD Signal Line 6.57
MACD Histogram -4.2234
Fundamentals Value
Market Cap 17.12 Billion
Num Shares 47 Million
EPS 18.13
Price-to-Earnings (P/E) Ratio 20.10
Price-to-Sales 4.53
Price-to-Book 1.75
PEG Ratio 1.30
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 373.74
Resistance 3 (R3) 373.14 369.40 372.17
Resistance 2 (R2) 369.40 367.01 369.70 371.64
Resistance 1 (R1) 366.87 365.53 368.14 367.47 371.12
Pivot Point 363.13 363.13 363.77 363.43 363.13
Support 1 (S1) 360.60 360.74 361.87 361.20 357.54
Support 2 (S2) 356.86 359.26 357.16 357.02
Support 3 (S3) 354.33 356.86 356.49
Support 4 (S4) 354.93